tbuckley/cabot-search huggingface dataset:
Salmonella enteritidis in Europa Occidentale 1995-98 - un rapporto di sorveglianza da Enter-net
Authors: I. S.T. Fisher
Journal: Eurosurveillance (1999)

Nella banca dati degli isolamenti di salmonella della rete Salm- net (che ora ha preso il nome di Enter-net) e stata identificata una diminuzione, in Europa Occidentale, dell'incidenza delle infezioni di Salmonella enteritidis tra il 1993 e il 1995, quando il numero degli isolati di S. enteritidis si e abbassato da 37.647 a 31.482 (1). Questa riduzione del 16% e stata riferita dai sette laboratori di riferimento nazionale per cui erano disponibili i dati. Comunque, a meta del 1997, e stato osservato che le notifiche di questo sierotipo stavano rapidamente aumentando (2). Adesso, i dati disponibili dal 1995 al 1998 per 12 paesi, mostrano che l'incremento e stato ridimensionato (figura).
P2.14-005 Determination of Optimal Cut off SUV Threshold for Auto-Contouring of GTV Using PETCT for Early Stage NSCLC
Authors: M. Patil, J. Agarwal, N. Purandare, S. Laskar, V. Rangrajan, A. Tibdewal, A. Chatterji, N. Mummudi, C. Pramesh, R. Kumar, A. Jha, S. Misra
Journal: Journal of Thoracic Oncology (2017)
STEM-18. RENIN-ANGIOTENSIN SYSTEM IDENTIFIED BY PHAGE DISPLAY SCREENING IS A NEW THERAPEUTIC TARGET FOR GLIOBLASTOMA AND REGULATES PROLIFERATION OF GLIOBLASTOMA STEM CELLS
Authors: Jongmyung (John) Kim, Qi Xie, Jeremy Rich, James Liu
Journal: Neuro-Oncology (2017)

Glioblastoma stem cells (GSCs) are tumor-initiating cells and contribute to chemo-radiation resistance of glioblastoma multiforme (GBM) with poor prognosis. Cell-cell interactions in GBM niche regulate and maintain GSCs leading to tumor progression. Secretory molecules from different cell types in GBM niche play significant roles in intercellular communications. Therefore, we utilized phage screening technology to identify the secretory molecules regulating GSCs-microenvironment interactions and target their communications. Phage display library consisting of 109 different combinations of 7-amino acid-length peptide sequences was screened for binding to GSCs both in vitro and in vivo. In vitro screening was performed against GSCs isolated from patient GBM tumors grown in culture following negative selection on non-GSCs. In vivo screening was performed by intravenous injections of the phage library into immunocompromised mice with intracranial primary GBM xenograft. Phage peptides that preferentially bound to the GSC population were recovered. BLAST analysis of the recovered peptides identified angiotensin I converting enzyme (ACE), a key protein in renin-angiotensin system (RAS). RT-qPCR, RNA-seq, ChIP-seq, and in silico data showed that GSCs highly expressed renin and angiotensinogen, components of RAS, and differentiated cancer cells and endothelial cells expressed ACE. TCGA and histologic analysis were also consistent with these findings. High expression of these RAS components correlated with poor patient survivals. To study the effect of RAS inhibitors on GSC proliferation, GSCs were treated with captopril, ramipril, lisinopril, and telmisartan, respectively. Interestingly, RAS inhibitors stimulated cell proliferation and tumorsphere formation. In conclusion, this study demonstrates that renin-angiotensin system as a potential therapeutic target for the treatment of glioblastoma.
P1.07-002 The Expression of PD-L1 Protein as a Prognostic Factor in Lung Squamous Cell Carcinoma
Authors: K. Takada, T. Okamoto, G. Toyokawa, Y. Kozuma, T. Matsubara, N. Haratake, T. Akamine, S. Takamori, M. Katsura, F. Shoji, Y. Oda, Y. Maehara
Journal: Journal of Thoracic Oncology (2017)
MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy
Authors: E. Dudnik, N. Peled, M. Wollner, A. Onn, A. Agbareya, H. Nechushtan, T. Kuznetsov, L. Roisman, A. Belilovski Rozenblum, S. Geva, A. Zer, J. Bar
Journal: Journal of Thoracic Oncology (2017)
A New DAWN for Imaging-Based Selection in the Treatment of Acute Stroke
Authors: Werner Hacke
Journal: New England Journal of Medicine (2017)

Two years ago, the publication of the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands),1 which investigated endovascular mechanical thrombectomy for the treatment of acute ischemic stroke, was called "a first step in the right direction." Since then, there have been five trials of thrombectomy for stroke that have shown positive outcomes. A pooled analysis of these trials2 confirmed the efficacy of thrombectomy that is performed within 6 hours after the onset of stroke in patients with occlusion of a cerebral large vessel (intracranial internal carotid artery or proximal middle cerebral . . .
Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery
Authors: C. David Mazer, Richard P. Whitlock, Dean A. Fergusson, Judith Hall, Emilie Belley-Cote, Katherine Connolly, Boris Khanykin, Alexander J. Gregory, Étienne de Médicis, Shay McGuinness, Alistair Royse, François M. Carrier, Paul J. Young, Juan C. Villar, Hilary P. Grocott, Manfred D. Seeberger, Stephen Fremes, François Lellouche, Summer Syed, Kelly Byrne, Sean M. Bagshaw, Nian C. Hwang, Chirag Mehta, Thomas W. Painter, Colin Royse, Subodh Verma, Gregory M.T. Hare, Ashley Cohen, Kevin E. Thorpe, Peter Jüni, Nadine Shehata
Journal: New England Journal of Medicine (2017)

The effect of a restrictive versus liberal red-cell transfusion strategy on clinical outcomes in patients undergoing cardiac surgery remains unclear.In this multicenter, open-label, noninferiority trial, we randomly assigned 5243 adults undergoing cardiac surgery who had a European System for Cardiac Operative Risk Evaluation (EuroSCORE) I of 6 or more (on a scale from 0 to 47, with higher scores indicating a higher risk of death after cardiac surgery) to a restrictive red-cell transfusion threshold (transfuse if hemoglobin level was <7.5 g per deciliter, starting from induction of anesthesia) or a liberal red-cell transfusion threshold (transfuse if hemoglobin level was <9.5 g per deciliter in the operating room or intensive care unit [ICU] or was <8.5 g per deciliter in the non-ICU ward). The primary composite outcome was death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis by hospital discharge or by day 28, whichever came first. Secondary outcomes included red-cell transfusion and other clinical outcomes.The primary outcome occurred in 11.4% of the patients in the restrictive-threshold group, as compared with 12.5% of those in the liberal-threshold group (absolute risk difference, -1.11 percentage points; 95% confidence interval [CI], -2.93 to 0.72; odds ratio, 0.90; 95% CI, 0.76 to 1.07; P<0.001 for noninferiority). Mortality was 3.0% in the restrictive-threshold group and 3.6% in the liberal-threshold group (odds ratio, 0.85; 95% CI, 0.62 to 1.16). Red-cell transfusion occurred in 52.3% of the patients in the restrictive-threshold group, as compared with 72.6% of those in the liberal-threshold group (odds ratio, 0.41; 95% CI, 0.37 to 0.47). There were no significant between-group differences with regard to the other secondary outcomes.In patients undergoing cardiac surgery who were at moderate-to-high risk for death, a restrictive strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to the composite outcome of death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis, with less blood transfused. (Funded by the Canadian Institutes of Health Research and others; TRICS III ClinicalTrials.gov number, NCT02042898 .).
EPID-06. GENOMIC AND CLINICAL CHARACTERIZATION OF GLIOBLASTOMA IN HISPANICS
Authors: Macarena De La Fuente, Michael E Ivan, John Kimball, Conner Hasse, Nicole Lin, Ricardo J Komotar, Antonio Omuro
Journal: Neuro-Oncology (2017)

Glioblastoma is the most common malignant primary brain tumor. The US census divides the American population into “Hispanic/Latino” and “Not Hispanic/Latino”, regardless of race. Hispanic/Latino is a rapidly growing population, but little is known about patterns of care, genomic profile and access to clinical trials in Hispanic patients diagnosed with glioblastoma. Retrospective review of glioblastoma in Hispanic patients evaluated at a tertiary referral center (University of Miami, FL). Analysis was restricted to patients seen after 06/2014, when routine molecular evaluation was incorporated into clinical care. A total of 54 self-declared Hispanic/Latino patients were identified. Among those, 48 were white, 6 from other races. Median age at diagnosis was 59 years. Twenty two (42%) patients had a gross total resection, 25 (47%) a subtotal resection and 7 (13%) biopsy only. Pathology review confirmed WHO grade IV GBM in all patients. Ten patients were diagnosed with lower grade glioma at initial diagnosis and had GBM at recurrence. IDH-1 R132H mutation was present in 14%. MGMT promoter was methylated in 27% of available samples. Next generation sequence (NGS) based assay was performed in 89% of the patients. The most commonly altered genes were EGFR, TP53, PTEN and TERT. Fifty three (98%) patients were treated with RT with temozolomide followed by temozolomide at diagnosis and a variety of treatment options at recurrence. Median overall survival for newly diagnosed GBM patients was 19 months. Ten (18%) patients were enrolled into clinical trials. In this series, Hispanic/Latino glioblastoma patients appear to have a similar genomic profiling as compared to general populations and achieved comparable survival and enrollment into clinical trials. This suggests that Hispanic/Latino populations with access to referral centers achieve outcomes comparable to the general population. Larger series and better racial reporting systems are needed to investigate the racial and genomic diversity within Hispanic/Latino population.
SURG-06. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR BRAIN METASTASIS
Authors: Andrew Sloan, Stephen B Tatter, Alireza Mohammadi, Kevin Judy, Sujit S Prabhu, Darren Lovick, Roukoz Chamoun, Veronica Chiang, Eric Leuthardt
Journal: Neuro-Oncology (2017)

Laser Interstitial Thermotherapy (LITT; sometimes called Stereotactic Laser Ablation or SLA,) is a minimally invasive procedure increasingly used to treat brain tumors. Previous reports have described small numbers of patients from a few centers. Here we describe the treatment and results of 40 patients with 83 brain metastasis treated at 9 centers 2015-2016 and compare this to outcomes in 68 patients with gliomas. De-identified data on patients undergoing LITT in a retrospective database were analyzed using standard statistical methods. The median age of patients treated for metastatic brain tumor was older than in patients with gliomas (59.1 yrs. vs. 53.8 yrs.; p =0.0422). Patients were predominately female (55%) and white (75%). Lesions were mostly recurrent (70%), or residual (5%), though 22.5% were newly diagnosed. The most frequent primaries were lung (52.6%), breast (13.2%), colon (5.3%) and melanoma (5.3%). Tumor locations include supratentorial (90.4%), thalamic 2.4%) and brainstem (7.2%). 32.5% were considered to be inoperable, 10% were unable to tolerate radiotherapy, and 2.5 % were unable to tolerate chemotherapy. Median pre-op KPS was 80 (+/-11.2) and median ECOG Performance status was 1.3(+/- 1.5). Previous treatments included steroids (87.5%) RT (71.1%), radiosurgery (54.2%), craniotomy (26.5%) and WBRT (14.5%). Metastasis treated with LITT were more often recurrent compared to gliomas (70% vs. 51.5%; p = 0.047) but were also smaller (7.9 cc vs 12.9cc; p =0.0083). Median lasing time was 38.6 min. Discharge status was home (79.5%), rehabilitation (10.3%), and SNF (5.1%). Average follow-up was 300.9 days and median survival was 421 days which was shorter than patients with glioma (568 days), but only 4.8% suffered a neurological death. LITT is safe and effective for the treatment of challenging brain metastasis including recurrent and otherwise inoperable tumors with survival and CNS survival equal or better than alternative treatments.
P2.02-052 A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care
Authors: J. Sun, Y. Li, C. Milbury, J. Skoletsky, C. Burns, W. Yip, J. Luo, N. Dewal, A. Johnson, K. Gowen, J. Tong, Y. He, J. He, J. White, S. Roels, A. Tsuji, J. Truesdell, E. Peters, H. Gilbert, C. Wu, E. Schleifman, C. Barrett, K. Thress, S. Jenkins, J. Elvin, G. Otto, D. Lipson, J. Ross, V. Miller, P.J. Stephens, M. Doherty, C. Vietz
Journal: Journal of Thoracic Oncology (2017)
IMMU-21. GLIOBLASTOMA CELLS EXPORT TENASCIN-C VIA MICROVESICLES TO SUPPRESS T CELL RESPONSES
Authors: Reza Mirzaei, Susobhan Sarkar, Andreas Faissner, V Wee Yong
Journal: Neuro-Oncology (2017)

The dismal prognosis of glioblastoma is contributed in part by the existence of stem-like brain tumor-initiating cells (BTICs) that are more radio- and chemo-resistant than their differentiated transformed progenies. This emphasizes the need for new approaches, particularly on therapies that instruct immune cells against BTICs. However, effective immunotherapies in glioblastoma remain elusive as immune cells such as T lymphocytes are suppressed by tumor cells. We have shown that BTICs and differentiated glioblastoma cells produce large amounts of tenascin-C (TNC), an extracellular matrix protein that promotes BTIC growth (Sarkar et al., Cancer Res 2017); whether and how TNC regulates T cell responses remain to be established. We stained human glioblastoma brain specimens and found TNC to be widely deposited including in vicinity of BTICs and T cells. In co-cultures, glioblastoma patient-derived BTICs inhibit the activation of T-cells, in part by the secretion of TNC as determined through neutralization by a series of monoclonal antibodies against TNC. Analysis of downstream signaling pathways of T cells following interaction with TNC showed attenuated phospho-protein levels. Of interest, TNC is mainly exported out of BTICs by microvesicles and microvesicle-depleted conditioned media were reduced in their capacity to suppress T cell responses. Moreover, TNC-depleted microvesicles had lower inhibitory effects on T cell activation. Finally, we found that circulating microvesicles from glioblastoma patients contained more TNC than those from control individuals. Collectively, our study reveals a novel pathway for therapeutic intervention: the suppression of T lymphocyte activity by BTICs through TNC cargoed within BTIC-secreted microvesicles.
P3.13-027 Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States
Authors: M. Behera, R. Jiang, K. Higgins, R. Pillai, T. Owonikoko, C. Belani, F. Khuri, K. Ward, W. Curran, S. Ramalingam
Journal: Journal of Thoracic Oncology (2017)
CBIO-01. TRANSCRIPTIONAL MODULATION OF BRACHYURY IN CHORDOMA
Authors: Ashlee Seldomridge, Heather Sonnemann, Jinkyu Jung, Amber Giles, Kristen McCampbell, Orieta Celiku, Kristan Meetze, Mark Gilbert, Claudia Palena, Deric M Park
Journal: Neuro-Oncology (2017)
MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
Authors: G. Chang, G. Curigliano, W. Lim, S. Viteri, F. Ciardiello, T. Hida, C. Lin, H. Murakami, M. Nishio, L. Paz-Ares, F. Cantero, C. Gabarroca, E. Gandossi, N. Kamsu-Kom, S. Pennaforte, M.-. Secouard-Faure, K. Park
Journal: Journal of Thoracic Oncology (2017)
P3.13-008 Lung Cancer Associated with Cystic Airspaces: Clinical, Imaging, Histopathological and Molecular Correlation
Authors: A. Snoeckx, P. Reyntiens, P. Pauwels, M. Spinhoven, P. Van Schil, L. Carp, P. Parizel, J. Van Meerbeeck
Journal: Journal of Thoracic Oncology (2017)
NCOG-16. A PILOT STUDY OF COGNITIVE FUNCTIONS, APOE AND AMYLOID IMAGING IN GLIOMA PATIENTS
Authors: Denise Correa, Maria Kryza-Lacombe, Xiaosun Zhou, Raymond Baser, Bradley Beattie, Zodina Beiene, John Humm, Lisa DeAngelis, Irene Orlow, Wolfgang Weber, Joseph Osborne
Journal: Neuro-Oncology (2017)

Many patients with brain tumors treated with radiotherapy (RT) and chemotherapy develop cognitive dysfunction, and recent studies suggest that the Apolipoprotein E (APOE) ε-4 allele may influence cognitive outcome in cancer patients. The APOE ε-4 allele is known to promote deposition of beta (β) amyloid in the cortex, and preliminary evidence suggests that RT may be associated with this process. However, it is unknown whether β-amyloid accumulation may contribute to treatment-related neurotoxicity. In this pilot study, we assessed neuropsychological functions and β-amyloid retention using 18F-florbetaben PET in a subset of brain tumor patients who participated in our study of APOE polymorphisms and cognitive functions. Twenty patients with gliomas treated with conformal RT ± chemotherapy participated in the study: 6 were APOE є-4 carriers and 14 were non-є-4 carriers. Patients completed a neuropsychological re-evaluation (mean time interval= 5 years, SD=0.83), and brain MRI and 18F-florbetaben PET scans. The results of Wilcoxon rank sums test comparisons between prior and current assessments showed a significant decline in selective attention (Brief Test of Attention, p=0.018), and a near significant decline in verbal learning (Hopkins Verbal learning Test-Learning, p=0.07). Comparisons by APOE status showed significant differences over time in attention and working memory (WAIS-III digits forward, p=0.028 & digits backward, p=0.032), with a decline among APOE є-4 carriers. Comparisons of PET 18F-florbetaben regional standard uptake value ratios (SUVRs) showed near significance differences for the medial temporal cortex (p=0.069) and the putamen (p=0.069), with non-є-4 carriers having higher SUVRs. The findings suggest that patients with gliomas may experience progressive worsening in attention and executive functions several years after treatment with conformal RT ± chemotherapy, and that the APOE є-4 allele may modulate cognitive decline.
QLIF-19. INITIAL PSYCHO-ONCOLOGICAL COUNSELLING IN NEURO-ONCOLOGY - ANALYSIS OF TOPICS AND NEEDS OF BRAIN TUMOUR PATIENTS
Authors: Stephanie Schipmann, Eric J Suero, Anna Frasch, Walter Stummer, Dorothee Wiewrodt
Journal: Neuro-Oncology (2017)

Diagnosis of a brain tumour is associated with a tremendous disruption of emotional, physical and social well-being. Due to the complexity of the disease and the affection of the central organ, the brain, brain tumour patients differ from other cancer patients. The purpose of this study was to evaluate the concerns and burdens presented by brain tumour patients during their initial psycho-oncological consultation. We performed a retrospective analysis of 53 patients with the diagnosis of either benign or malignant brain tumour, seeking counsel by a neurosurgeon specialised in psycho-oncology. We performed a thematic analysis of the interviews at first consultation identifying themes and patterns and created thematic categories. The main concerns of the patients presented during the first consultations were psychological problems, reported by 40 patients (75.5%). Death and dying was mentioned by more than half of the patients (n=30, 56.6%). In addition, 62.3% of the patients (n=33) asked for information regarding the medical treatment and diagnosis. With our study we created greater awareness of the psychological needs of brain tumour patients in order to define treatment strategies for this important aspect of disease. We showed that there is a need for patients to talk about death even during the initial consultation. Therapist in a neuro-oncological setting should be prepared for topics like that and should even have a medical background in neurosurgery in order to provide the patients with medical details and to better understand the impact of the disease.
GENE-47. EVALUATING GLIOMA RISK ASSOCIATED WITH EXTENT OF EUROPEAN ADMIXTURE IN AFRICAN-AMERICANS AND LATINOS
Authors: Quinn Ostrom, Kathleen Egan, Burt Nabors, Christopher Amos, Georgina Armstrong, Jonine Bernstein, Sajeel Chowdhary, Elizabeth Claus, Jeanette Eckel-Passow, Travis Gerke, Richard Houlston, Dora Il’yasova, Robert Jenkins, Christoffer Johansen, Daniel Lachance, Rose Lai, Renato LaRocca, Ching Lau, Ryan Merrell, Jeffrey J Olson, Sara Olson, Siegal Sadetzki, Joellen Schildkraut, Sanjay Shete, Reid Thompson, Margaret Wrensch, John Wiencke, Beatrice Melin, Melissa Bondy, Jill Barnholtz-Sloan
Journal: Neuro-Oncology (2017)

Glioma incidence is highest in non-Hispanic Whites, where it occurs ~2x as frequently compared with other race/ethnicity groups. Glioma GWAS have included European-ancestry (EA) populations only, and is unknown whether identified variants are associated with glioma in non-EA populations. African Americans (AA) and Hispanics are admixed populations with varying proportions of EA. Here we attempted to assess whether excess EA at risk loci (Melin et al, Nature Genetics, 2017) was associated with glioma risk in non-EA populations. We identified 197 AA cases, 168 AA controls, 269 Hispanic Whites and 123 Hispanic Whites controls within the Glioma International Case-Control Study and GliomaSE Study. Local ancestry (LA) was estimated using RFMix with four 1,000 genomes project continental reference populations (African, American, East Asian, and European). Global ancestry was calculated by averaging LA. We evaluated differences in local EA between cases and controls using logistic regression within 500kb of 26 previously identified risk variants (766 SNPs with minor allele frequency≥0.01) for all glioma, GBM and non-GBM. Results were considered significant at p<1.1x10-5 (adjusted for 4,596 tests). All analyses were performed stratified by self-reported race/ethnicity. AA cases had higher global EA (GEA) than controls (28.3% vs 23.6%, p=0.0009), there was no significant difference in GEA in Hispanic White cases and controls. There was a nominal association in AA between increased local EA (LEA) and all glioma at 3p14.1 (pminimum=0.001), and with GBM at 5p15.33 (pminimum=0.002). In Hispanic Whites, there was a nominal association between increased LEA and GBM at 12q23.33 (pminimum=0.008), and at 17p13.1 (pminimum=0.007). EA populations show increased susceptibility to glioma, and it is possible that increased EA increases risk of glioma in admixed populations. These results suggest that glioma risk may be associated both with increased GEA in AA and increased LEA at some previously identified variants in AA and Hispanic whites.